Yazen Raises €50m in Round Led by Verdane

Yazen, a startup building digital weight loss treatments, has raised €50m in a round led by the Nordic growth investor Verdane, Sifted reports exclusively.

The figure is the hard number at the center of the deal. It is a substantial ticket for a European health tech company operating in the weight loss category — a segment now dominated by GLP-1 era spending and rapidly growing consumer demand.

Who is putting in the money?

Verdane, a growth equity firm with a long track record of backing Northern European technology companies, led the round, according to Sifted's exclusive report. The presence of a single named lead investor of Verdane's scale signals a growth-stage commitment rather than a fragmented seed syndicate.

Sifted, the Financial Times-backed startup news outlet, broke the story. Its reporting identifies the round size and the lead backer; the startup's full cap table behind the round was not disclosed in the report.

What does Yazen actually do?

Yazen sits in the digital health category focused on obesity and weight management. The company delivers weight loss treatments to consumers — a market that has expanded sharply as pharmaceutical options such as GLP-1 medications have moved weight care from a lifestyle topic into mainstream medicine.

Digital-first providers like Yazen compete by pairing medical treatment with app-based care, remote prescribing and ongoing clinical follow-up. That model has attracted significant venture capital across Europe over the past two years, as payers and consumers shift toward telehealth delivery.

Why does a €50m round matter now?

The size of the cheque stands out against a European funding market that has tightened since 2022. Growth rounds of this magnitude in digital health have become less common, and weight care is one of the few consumer health verticals where investors are still writing large cheques.

A round led by Verdane also fits the firm's pattern of backing scaled consumer and health-adjacent technology businesses across the Nordics and Northern Europe. For Yazen, the capital provides runway to expand treatment delivery, deepen clinical operations and defend position in a category where well-funded competitors are consolidating.

What comes next?

Neither Yazen nor Verdane has publicly detailed the deployment plan for the €50m, according to the Sifted report. Expect the startup to put the capital behind market expansion and product depth as demand for digital weight loss treatment continues to grow across Europe.